Screener / SEC EDGAR /CIK 0001809987 /10-K filed Feb 19, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Technology · Measuring Instruments

Mirion Technologies, Inc. MIR

Compare with peers Embed
The 10-K against last year's

211 changes: 34 added, 31 removed, 142 reworded, 4 quiet changes

10-K Feb 19, 2026 vs Feb 26, 2025

10-K 0001628280-26-009869 (Feb 19, 2026) vs 10-K 0001628280-25-008233 (Feb 26, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

59 paragraphs · 7 new · 41 reworded · 8 gone · 10-K Feb 19, 2026 against Feb 26, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 5 · 47% changed Every version of it
International tariffs, including Our operating results may be impacted by the effects of, and changes in, worldwide economic conditions, international trade, tariffs that affect our products or components within our products, and retaliatory countermeasures, export controls and other trade barriers or barriers, global trade wars or domestic preferences which could increase our costs and materially and adversely affect our business, results of operations and financial condition. Our global business, operations, and the execution of our business could be negatively affected by tariffs, strategies and plans are subject to global competition and economic and geopolitical risks that are beyond our control, such as, among other things, tariffs and retaliatory countermeasures, trade barriers and other governmental protectionist measures, measures impacting international trade agreements or imposing trade restrictions, any of which can be, and have negatively affect us. The global economy has been imposed unpredictably and without much or any prior notice. impacted by geopolitical tensions. There is currently significant uncertainty about the future trade relationships between the United States and various other countries, most significantly Russia, Canada, Mexico, China and China. Further escalation of specific trade tensions, including those between the EU. Certain U.S. and China, or more broadly in global trade conflicts, could materially and adversely affect the Company’s business and operations. The U.S. government and other governments have imposed export controls and tariffs on certain products and certain components that we import into into, and export out of, the United States from suppliers in such jurisdictions States, and we, our customers, suppliers, and partners may become subject to enhanced or extraordinary additional tariffs and such additional export controls and our products and services may be subject to increased competition outside of the United States. In addition, geopolitical tensions could result in, among other things, cyberattacks, supply chain disruptions, higher energy and other commodity costs, lower demand, changes to foreign exchange rates and financial markets. Additional tariffs and trade restrictions may result in the near future. Further, the U.S. may impose global reciprocal tariffs on all countries it trades with. The imposition of global additional tariffs could increase our increased manufacturing costs and require us product pricing, further supply chain disruptions, limit access to raise prices on end markets and lower profitability. We also generate a significant amount of our products, revenue outside of the United States which may negatively impact be adversely affected by tariffs and trade controls imposed by other countries. Revenue generated from outside of North America accounted for approximately 37.1% of our net sales for the demand year ended December 31, 2025, and approximately 37.0% of our net sales for the year ended December 31, 2024, and international sales are expected to remain a material percentage of our products total revenue in the affected market. future periods. If we are not successful in offsetting the impact of any such added tariffs, export controls, trade barriers, and other geopolitical disruptions, our business revenue, gross margins, business, results of operations and financial condition may be adversely affected.
Paragraph 59 · 44% changed Every version of it
Our Charter includes forum selection clauses, which could discourage claims or limit stockholders’ ability to make a claim against us, our directors, officers, or other employees. Our Charter generally provides that the Court of Chancery in Delaware is the exclusive forum for any stockholder (including a beneficial owner) to bring derivative actions and related claims against the Company or its directors, officers or employees and our Charter provides that the federal district courts of the United States are the exclusive forum for any complaint under the Securities Act. However, this does not apply to suits under the Exchange Act or other claims exclusively under U.S. federal jurisdiction. These clauses may discourage claims or limit stockholders’ ability to submit claims in a judicial forum that they find favorable, potentially increasing increase costs for those seeking to bring claims. If a court finds these clauses inapplicable or unenforceable, it could result in additional costs and negatively impact our business, results of operations and financial condition.
Paragraph 2 · 44% changed Every version of it
You should carefully consider the following risk factors, together with all of the other information included in this Annual Report on Form 10-K, before making an investment decision. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances may have an adverse effect on our business, results of operations and financial condition. The These risks described below are not the only risks we face but represent known risks we believe are material. Additional risks and uncertainties not currently known to us, or those that we currently view deem to be immaterial, may could also materially adversely affect our business, results of operations and financial condition. condition or future results.
Paragraph 8 · 41% changed Every version of it
agreement In April 2023, a Russian customer claimed $19.3 million in liquidated damages for delays on a Hungarian project, later increasing the claim to $21 million, despite a $14 million contractual cap (all amounts converted from Euros to U.S. Dollars). In November 2024, the parties reached a settlement and agreed to modify the underlying contract, the claim was rescinded, and the contract. The parties are now working on implementing the terms of the settlement which is complicated by the current sanctions regime. The modification was accounted for under ASC 606 Revenue Recognition which resulted in an immaterial impact to the Statement of Operations for the year ended December 31, 2024. In June 2023, the same Russian customer made a demand against the Company for the return of all payments received by the Company ($10.2 million) related to a Finland project cancelled in May 2022. In September 2024, the Company entered into a settlement agreement with the customer and agreed to refund €4.4 million which is complicated by the current sanctions regime. The amount is included in Accrued expenses and other current liabilities in the Condensed Consolidated Balance Sheet as of December 31, 2024, and the settlement resulted in an immaterial impact to the Condensed Statement of Operations for the year ended December 31, 2024.
Paragraph 35 · 39% changed Every version of it
Our ability to compete successfully and achieve future growth will depend on our ability to obtain, maintain, protect, defend and enforce our intellectual property and to operate without infringing, misappropriating or otherwise violating the intellectual property of others. Our intellectual property is an essential asset of vital to our business and insufficient protection or invalidation of these rights could significantly affect harm our business, results of operations and financial condition, including forcing us to, among other things, rebrand or re-design our affected products. Additionally, foreign Foreign laws may not adequately protect our intellectual property rights, including due to a lack of adequate remedies and enforcement mechanisms, posing considerable increasing risks as we conduct a substantial portion of our operations and a majority of our sales outside of the United States. In addition, advances in artificial intelligence and the increasingly widespread use of such technology by us, our third parties or others, including generative artificial intelligence tools, may increase the risk of unauthorized access to, or use of, our intellectual property and unauthorized or unintended exposure of our confidential information and proprietary information, all of which could adversely affect the value of our intellectual property, including our brands, our trade secrets and our investment in research and development. Third parties have claimed and may continue to claim that we have infringed upon, misappropriated infringement, misappropriation or misused misuse of their proprietary rights. These allegations have led and may continue rights, leading to lead to litigation, necessitating significant costly litigation. Unsuccessful defense costs, even if we are successful. If we are not successful in defending against such claims, we claims could be required to pay result in substantial damages, halt halted product sales, expensive technology changes, or the production, use and sale of certain products, invest heavily in developing or acquiring non-infringing technology, cease certain processes, need to obtain licenses to use the infringed technology or indemnify our customers. We currently have in effect, and may in the future enter into, agreements to defend, indemnify and hold harmless our customers or suppliers against damages and costs from alleged infringement, misappropriation or other violation by our products of third-party patents, trademarks or other proprietary rights. Litigation related to such obligations could be costly and divert the efforts of our technical and management personnel, regardless of the outcome. Our insurance does not cover intellectual property infringement. Any of these results the foregoing would materially and adversely affect our business, results of operations and financial condition.
Paragraph 9 · 38% changed Every version of it
We have made and plan to continue to make acquisitions, investments and divestitures that involve numerous risks and uncertainties. We pursue growth by selectively acquiring and investing in, businesses, products or technologies, while also divesting businesses that no longer align with our strategic plans. However, there can be no assurance that suitable opportunities will be identified or that transactions will close on favorable terms. The expected benefits may not materialize, and such activities can introduce risks, including competition for attractive or promising businesses or assets, financing needs, and regulatory approvals. The sale of Financing acquisitions through equity or equity-linked securities debt may dilute our stockholders or issuance of debt to finance any such acquisitions could result in dilution to our stockholders. The incurrence of indebtedness would result in increased fixed obligations and could also include covenants or other restrictions that would impede our ability to manage our operations. increase financial obligations. Divestitures also require significant can be time and resources, could disrupt consuming, disruptive our business, may not close on the expected timing or at all, have in the past resulted in additional costs following the transaction and may continue to do so in the future. Potential and actual transactions could also divert management's attention, and could potentially deplete corporate resources and adversely impact the Company's Company’s business, results of operations and financial condition.
Paragraph 21 · 38% changed Every version of it
We derive a substantial portion of our U.S. revenue from contracts with U.S. governmental customers or their contractors, and any shutdown or other development where such customers may be required to reduce their spending, cancel contracts, initiate audits and investigations, and or require unusual or more onerous contractual terms. terms could materially and adversely affect us. A substantial portion of our business is driven by relies on government budgets and spending, such as nuclear power plants and medicine, and a substantial portion of our revenue medicine. Revenue is derived from often tied to government customers or their contractors or sub-contractors. Any reduction in the resources or government funding of our customers, including funding, such as a result of a government shutdown, the U.S. government's failure to raise the debt ceiling, or other governmental action or order to reduce governmental budgets and spending generally, including in non-U.S. countries, general budget cuts could reduce our sales and impede our ability to generate revenue. Any change Changes in policy regarding capital spending, spending policies or reduction, or increased scrutiny of the capital government budgets of U.S. government customers could also reduce demand for our solutions and could also result in audits and investigations. In addition, even Even when our direct customer is not a government entity, selling to non-government entities, we must comply with stringent strict procurement processes applicable to for government contractors and subcontracts, in particular in the United States, States. European Union and United Kingdom. Furthermore, we have bid, and may in the future submit bids, Bids for government contracts that may require government-specific terms such as various levels of security clearances with the Department of Defense or Department of Energy, or that supplies be U.S-made, and similar such measures in other countries, including compliance with regulations like the European Union and the United Kingdom. Buy-American Act. Obtaining and maintaining security clearances involves is a lengthy process, such clearances process and may ultimately be denied or revoked and it revoked. Recruiting qualified employees for these clearances can also be difficult to identify, recruit and retain employees qualified for security clearances. If the current requirements of the Buy-American Act are revised, it could also impede our ability to sell to the U.S. government. difficult. We are subject from time to time to government audits and investigations, and if any such audit or investigation results investigations which can result in an adverse finding to us, we may be subject to financial penalties and debarment debarment, financial penalties, contract delays, or otherwise be unable to continue doing loss of business with the applicable customer. Initiatives to reduce if adverse findings occur. Increased government spending could also drive additional audits and investigations. cuts may lead to more audits. Failure to secure or retain security meet requirements (security clearances, to qualify products as U.S.-made or adverse findings in audits or investigations product qualifications, audit standards) could result in contract delays, termination, penalties and loss of future business opportunities, any of which could adversely affect impact our business, results of operations and financial condition.
Paragraph 52 · 37% changed Every version of it
Our indebtedness could adversely affect our financial condition. As of December 31, 2024, 2025, we had $694.6 $450.0 million aggregate principal amount of indebtedness outstanding under our senior secured term loan facility (the “Term Loan Facility”) and there is additional availability under our senior secured revolving facility (the “Revolving Facility” and, together with the Term Loan Facility, the “Credit Facilities”) of up to $90.0 $175.0 million. In addition, our Credit Facilities bear interest based on variable interest rates which have recently increased and may increase further from time to time in the future. Continued increases in interest rates will increase the cost of servicing our outstanding indebtedness as well incurring new indebtedness and refinancing our outstanding indebtedness, and could materially and adversely affect our business, results of operations and financial condition. Our indebtedness could have important consequences to us, such as requiring us to dedicate a significant portion of our cash flows to debt payments, reducing available funds for other needs, increasing vulnerability to economic changes, limiting business flexibility, placing us at a competitive disadvantage, restricting future financing options, and exposing us to variable interest rate risks. If we fail to make scheduled payments on our debt, we risk default, which could lead to lenders terminating their commitments, demanding immediate repayment, or foreclosing on secured assets, potentially resulting in bankruptcy or liquidation.

MD&A

192 paragraphs · 27 new · 70 reworded · 23 gone · 10-K Feb 19, 2026 against Feb 26, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 44 · 49% changed
In response The Company's 2021 Credit Agreement provides for an $830.0 million senior secure first lien term loan facility (initially scheduled to the current interest rate environment, mature in October 2028). On June 5, 2025, the Company refinanced utilized funds from the Credit Facilities offering of the 2030 Notes completed on May 22, 2024 23, 2025 to repay $244.6 million in outstanding principal and reduced $8.3 million in accrued interest as well as extend the maturity date of the term loan facility applicable margin rate to the greater of the Secured Overnight Financing Rate ("SOFR") or 0.50% plus 2.25% (previously 2.75% prior to the refinancing) and reduced the credit spread based upon rate term to 0%. June 5, 2032. There were no other changes to the terms of the Credit Facilities as a result of the refinancing. The change was accounted for prospectively as a partial debt modification extinguishment in accordance with ASC 470-50, Debt—Modifications Debt - Modifications and Extinguishments. Refer to discussion included within Liquidity and Capital Resources for more details.
Paragraph 82 · 48% changed
Income from operations was $22.3 Corporate and other costs were $96.5 million for the year ended December 31, 2024 2025 and loss from operations was $13.0 $76.4 million for the year ended December 31, 2023, respectively, representing 2024, which represents an increase in income loss from operations of $9.3 $20.1 million. The increase in income from operations period over versus the comparable period was largely due to the increased revenues noted previously, lower bonus predominantly driven by one-time mergers and acquisition advisor expenses of $3.3 million, $15.7 million and a net impact from the ec2 business of $1.9 million. Partially offsetting the increase in income were higher restructuring and related impairment increased compensation costs of $4.2 $6.2 million, partially offset by decreased stock compensation costs of $1.7 million (predominantly from lower incentive compensation) and $0.9 million of additional bad debt expense in the current year. other general corporate expenses.
Paragraph 60 · 45% changed
Cost of revenues related to the Nuclear & Safety Medical segment increased $10.0 decreased $2.8 million period over period. The increase was period primarily driven by increased revenues over due to favorable margins as a result of product mix in the same period and inflation, current period, partially offset by a positive product mix from higher margin projects and products in the current year, projects execution timing, and other cost saving initiatives. inflationary impacts.
Paragraph 79 · 45% changed
Medical segment revenues were $310.8 million for the year ended December 31, 2025 and $299.7 million for the year ended December 31, 2024 and $284.5 million for the year ended December 31, 2023, 2024, which is an increase of $15.2 $11.1 million. Revenues increased $12.1 million due to $6.0 million of price increases increases, $2.7 million of revenue recoveries from operational delays in the comparable prior period, $1.4 million of foreign exchange fluctuations, and $1.0 million in organic volume growth. Organic volume growth excluding China and Russia, and $11.4 million due to the acquisition of the ec2 business. Partially offsetting the increase in the Medical segment revenues period over period were reduced revenues is down from the disposal of Rehab by $3.6 million and reduced revenues from China , due to increased regulation requirements, and Russia due to geopolitical impacts, compared to the prior year by $4.7 million. as a result of softer demand within the cancer care end-market in certain geographies.
Paragraph 54 · 44% changed
Partially offsetting these items were an increase in interest expense the exchange rate between the US Dollar and the Euro in the current year, period, decreased amortization of intangible assets, and a $62.4 $5.3 million change decrease in the loss from fair value of warrant liabilities, liabilities in the prior year that no longer impacts the current year. Partially offsetting these items were increased mergers and acquisition expenses, increased compensation costs in the current year, a $2.6 $5.8 million loss on debt extinguishment in the year ended December 31, 2023. current period, and increased depreciation expense.
Paragraph 64 · 42% changed
Corporate SG&A expenses were $70.2 $88.1 million for the year ended December 31, 2023 2025 and $90.0 $70.8 million for the year ended December 31, 2022. 2024. The lower higher SG&A expenses of $19.8 $17.3 million were driven by a decrease in current period expenses associated with mergers and acquisitions and increased compensation costs, partially offset by decreased stock-based compensation expense under the 2021 Omnibus Incentive Plan and Profit Interests (see Note 14, Stock-Based Compensation, to the general corporate spend.
Paragraph 59 · 42% changed
Cost of revenues related to the Nuclear & Safety segment increased $10.0 $28.5 million period over period. The increase was primarily driven by increased revenues over the same costs of material and labor of $7.4 million, foreign exchange impacts of $7.3 million, costs related to current period acquisitions of $6.2 million, domestic volume growth of $4.7 million, and inflation, partially offset by a positive product mix from higher margin projects and products in the current year, projects execution timing, and other cost saving initiatives. increased depreciation of $2.9 million.
Paragraph 152 · 40% changed
Net Operating activities provided net cash used in financing activities was $3.3 of $143.3 million for the year ended December 31, 2024 2025, as compared to net cash provided of $22.6 $99.1 million during for the year ended December 31, 2023. 2024. The decrease increase in net cash provided of $25.9 million by operating activities was $44.2 million. The change is primarily due to the $22.7 an increase in net income of $66.4 million change relating to the $150.0 and $10.2 million of gross proceeds received from the T. Rowe direct investment changes in the prior year various items in net working capital, partially offset by debt repayments made with those funds $19.6 million of $127.3 million. foreign currency translation adjustments and $12.4 million from the decrease in depreciation and amortization expense.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors382 words changed in this paragraph; it is 37% similar to last year's version.
International tariffs, including Our operating results may be impacted by the effects of, and changes in, worldwide economic conditions, international trade, tariffs that affect our products or components within our products, and retaliatory countermeasures, export controls and other trade barriers or barriers, global trade wars or domestic preferences which could increase our costs and materially and adversely affect our business, results of operations and financial condition. Our global business, operations, and the execution of our business could be negatively affected by tariffs, strategies and plans are subject to global competition and economic and geopolitical risks that are beyond our control, such as, among other things, tariffs and retaliatory countermeasures, trade barriers and other governmental protectionist measures, measures impacting international trade agreements or imposing trade restrictions, any of which can be, and have negatively affect us. The global economy has been imposed unpredictably and without much or any prior notice. impacted by geopolitical tensions. There is currently significant uncertainty about the future trade relationships between the United States and various other countries, most significantly Russia, Canada, Mexico, China and China. Further escalation of specific trade tensions, including those between the EU. Certain U.S. and China, or more broadly in global trade conflicts, could materially and adversely affect the Company’s business and operations. The U.S. government and other governments have imposed export controls and tariffs on certain products and certain components that we import into into, and export out of, the United States from suppliers in such jurisdictions States, and we, our customers, suppliers, and partners may become subject to enhanced or extraordinary additional tariffs and such additional export controls and our products and services may be subject to increased competition outside of the United States. In addition, geopolitical tensions could result in, among other things, cyberattacks, supply chain disruptions, higher energy and other commodity costs, lower demand, changes to foreign exchange rates and financial markets. Additional tariffs and trade restrictions may result in the near future. Further, the U.S. may impose global reciprocal tariffs on all countries it trades with. The imposition of global additional tariffs could increase our increased manufacturing costs and require us product pricing, further supply chain disruptions, limit access to raise prices on end markets and lower profitability. We also generate a significant amount of our products, revenue outside of the United States which may negatively impact be adversely affected by tariffs and trade controls imposed by other countries. Revenue generated from outside of North America accounted for approximately 37.1% of our net sales for the demand year ended December 31, 2025, and approximately 37.0% of our net sales for the year ended December 31, 2024, and international sales are expected to remain a material percentage of our products total revenue in the affected market. future periods. If we are not successful in offsetting the impact of any such added tariffs, export controls, trade barriers, and other geopolitical disruptions, our business revenue, gross margins, business, results of operations and financial condition may be adversely affected.

Source: Item 1A, 10-K 0001628280-26-009869 vs Item 1A, 10-K 0001628280-25-008233

Accounting Policies203 words changed in this paragraph; it is 45% similar to last year's version.
On April 18, 2024, the Company called the Public Warrants for redemption per the Company's rights under the warrant agreement. After April 18, 2024 and prior to 5:00 pm New York City time on Monday, May 20, 2024 (the "Redemption Date"), Public Warrant holders were entitled to exercise (i) in cash, at an exercise price of $11.50 per share of Class A common stock, or (ii) on a cashless basis in which the exercising holder was entitled to receive 0.22 shares of Class A common stock per Warrant. The number of shares provided to the warrant holder was determined in accordance with the terms of the warrant agreement, whereby the number of shares received in a cashless exercise was based upon the Redemption Date and the average last reported sale price of Class A common stock for the ten trading days ending on the third trading day prior to the notice of Redemption Date. The Public Warrants were valued using the listed trading price as of close on the trading day prior to the relevant settlement date of exercise. Any Warrants not exercised by the Redemption Date were automatically redeemed by the Company at a price of $0.10 per Warrant. In connection with the Redemption, approximately 18,076,416 Public Warrants were exercised, representing approximately 96% of the outstanding Public Warrants, and 3,978,418 shares of Class A common stock were issued upon exercise of such Warrants. Total cash proceeds generated from exercises of the Public Warrants were immaterial, and the Company made an immaterial redemption payment to the holders of the 673,363 redeemed Public Warrants. Following the Redemption Date, the Public Warrants stopped trading on NYSE and were delisted. No Public Warrants were outstanding as of December 31, 2024.

Source: Item 8, Note 1 – Nature of Business and Summary of Significant Accounting Policies, 10-K 0001628280-26-009869 vs Item 8, Note 1 – Nature of Business and Summary of Significant Accounting Policies, 10-K 0001628280-25-008233

MD&A200 words changed in this paragraph; it is 38% similar to last year's version.
Revolving Line of Credit - The revolving line of credit arrangement has initially had a five year term (expiring October 2026) and bears bore interest at the greater of LIBOR (through June 30, 2023) / SOFR (subsequent to June 2023) or 0%, plus 2.75%. 2.25%. The agreement requires the payment of a commitment fee of 0.50% per annum for unused commitments. The revolving line of credit matures in October 2026, at which time all outstanding revolving facility loans and accrued and unpaid interest are due. Any outstanding letters of credit reduce the availability terms of the revolving line of credit. There was no outstanding balance under credit were amended on March 21, 2025, through Amendment No. 4 to the arrangement as of December 31, 2024, and December 31, 2023. Additionally, the Company has standby letters of credit issued under its 2021 Credit Agreement ("Amendment No. 4"). Under Amendment No. 4, revolving credit commitments from lenders increased from $90.0 million to $175.0 million, and the maturity date extended to March 21, 2030, subject to a "springing" maturity date that reduce is 91 days prior to the availability maturity date of the outstanding term loan under the revolver 2021 Credit Agreement (but only to the extent the outstanding principal amount of $17.9 the term loan exceeds $100.0 million and $16.7 million as of December 31, 2024, and December 31, 2023, respectively. The amount available on the revolver as date of December 31, 2024, determination, and December 31, 2023 was approximately $72.1 million and $73.3 million, respectively. a final statement maturity date that is early than 91 days after March 21, 2030).

Source: Item 7, 10-K 0001628280-26-009869 vs Item 7, 10-K 0001628280-25-008233

Legal Proceedings48 words changed in this paragraph; it is 71% similar to last year's version.
In June 2023, the same Russian customer made a demand against the Company for the return of all payments received by the Company ($10.2 million) related to a Finland nuclear power plant project cancelled in May 2022. In September 2024, the Company entered into a settlement agreement with the customer agreeing to refund €4.4 million to the customer. The amount is included customer, which was paid in Accrued expenses and other current liabilities in the Condensed Consolidated Balance Sheet as of December 31, 2024, and the settlement resulted in an immaterial impact to the Consolidated Statement of Operations for the fiscal year ended December 31, 2024. June 2025.

Source: Item 3, via Note 11 – Commitments and Contingencies, 10-K 0001628280-26-009869 vs Item 3, via Note 10 – Commitments and Contingencies, 10-K 0001628280-25-008233

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of MIR's Risk Factors and MD&A, 10-K Feb 19, 2026 against 10-K Feb 26, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
We operate in complex markets and regulatory environments and that involves significant risk. You should carefully consider the following risk factors before making an investment decision as they may have an adverse effect on our business, results of operations and financial condition:
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
Following the Paragon acquisition, our growth strategy relies in part on plans to supply our products and services to SMRs and other advanced reactors in the U.S., an emerging market that may grow more slowly than we expect. Our Nuclear and Safety growth strategy relies on market research that estimates that the market for SMRs will surge, driven by a global growth in energy, and specifically electricity demand, and we have accordingly pursued entering into strategic agreements with a number of SMR companies in the U.S. However, these companies face multiple commercialization obstacles including reactor design, regulatory licensing, and securing customers willing and able to make large investments in emerging nuclear technologies. Each SMR developer faces unique risks, including risks related to technology, regulatory approvals, and financing. Even for those SMR companies that succeed, the cost curves that will be required for successful commercialization at scale will be aggressive and competition will be fierce among them, and also from other cost-competitive energy solutions. Further, many of these SMR companies are new entrants to the nuclear market and may fail operationally even if they develop a successful reactor, which may negatively impact the entire market. Our assumptions, estimates and plans about the SMR market may not be correct or they may change at any time, and our revenue may be subject to volatility as our SMR partners succeed, delay or cancel their projects, or fail altogether, which could cause material and adverse impacts on our business, results of operations and financial condition.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
In July 2025 and December 2025 we acquired Certrec and Paragon, respectively. These acquisitions may not meet our expectations. Their success, including anticipated benefits, will depend, in part, on our ability to successfully integrate our respective organizations without materially disrupting existing business and strategic relationships. If we experience difficulties in the integration process, we may not fully realize the anticipated benefits of the acquisitions in a timely manner, or at all.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
The use of Artificial Intelligence (AI) and machine learning in our business and operations may result in legal liability, regulatory action, increased compliance obligations, competitive or reputational harm, ethical or other concerns and adversely affect our business, financial condition and results of operations. We leverage artificial intelligence, including generative artificial intelligence and machine learning in certain of our business operations and may also use products and services from third parties that use artificial intelligence technology. Our competitors or other third parties may incorporate artificial intelligence into their operational processes more quickly or more successfully than us, which could have a material adverse effect on our competitive position, reputation and operations. In addition, there are significant risks involved in developing and deploying artificial intelligence and there can be no assurance that our use of artificial intelligence will increase our efficiency or profitability or be beneficial to our business. Laws and regulations regarding artificial intelligence technologies are rapidly evolving and complex, including in the areas of intellectual property, cybersecurity, privacy and data protection. We have implemented policies and controls to mitigate many of the novel risks presented by these new technologies but compliance with new or changing laws, regulations or industry standards relating to artificial intelligence may impose significant costs and limit our ability to develop, deploy or use artificial intelligence technologies in our business. There has been an increase in artificial intelligence related litigation and government regulatory actions targeting the design, deployment and other uses of artificial intelligence and claiming liability under numerous areas of law, such a consumer protection, product liability, privacy, intellectual property, securities and defamation. Any of these risks could have an adverse effect on our business, results of operations and financial condition.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
to, or use of our data and systems, could far exceed the limits of our insurance coverage for such events. Any significant data breach or misuse of confidential information may result in significant costs, litigation and regulatory enforcement actions, harm our reputation, and therefore, may have a material adverse impact on our business, reputation, results of operations and financial condition.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
Conversion of our Convertible Notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our Class A common stock. Upon conversion of our Convertible Notes (as defined below), we have the option to pay or deliver, cash, shares of our Class A common stock, or a combination of both. If we elect to settle our conversion obligation in shares of our Class A common stock or a combination of cash and shares of our Class A common stock, any sales in the public market of our Class A common stock issuable upon such conversion could adversely affect prevailing market prices of our Class A common stock. In addition, the existence of our Convertible Notes may encourage short selling by market participants because the conversion of the notes could be used to satisfy short positions, or anticipated conversion of our Convertible Notes into shares of our Class A common stock could depress the price of our Class A common stock.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
The conditional conversion feature of our Convertible Notes, if triggered, may adversely affect our financial condition and operating results. In the event the conditional conversion feature of our Convertible Notes is triggered, holders of such notes will be entitled to convert their notes at any time during specified periods at their option. If one or more holders elect to convert their Convertible Notes, we can elect to satisfy our conversion obligation by delivering solely shares of our Class A common stock (other than paying cash in lieu of delivering any fractional share) or we can settle a portion or all of our conversion obligation through the payment of cash. If we elected to settle a portion or all of our conversion obligations through the payment of cash, it could adversely affect our liquidity. In addition, even if holders do not elect to convert their Convertible Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.
Read it in 10-K Feb 19, 2026 at sec.gov
RemovedRisk Factors
The broader consequences of the conflict between Russia and Ukraine cannot be predicted, nor can we predict the ultimate impact of other volatile conditions in the Middle East and Asia, including the South China Sea, on the global economy or our business, results of operations, and financial condition. We could be prevented from selling our products or required to cease work on certain customer projects if additional sanctions related to these or other conflicts are imposed. These volatile geopolitical conditions have heightened other risks disclosed herein, including through increased inflation, limited availability of certain commodities, supply chain disruption, disruptions to our global technology infrastructure, including cyberattacks, increased terrorist activities, volatility or disruption in the capital markets, and delays or cancellations of customer projects, each of which could adversely affect our business, results of operations, and financial condition.
Read it in 10-K Feb 26, 2025 at sec.gov
Show the other 59
RemovedRisk Factors
contract period. We may experience cost overruns due to these factors resulting in losses or reduced profitability which could materially and adversely affect our business, results of operations and financial condition.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
inability to secure new government contracts, contract modification or termination, criminal and civil penalties and fines, and loss of business opportunities, any of which could adversely affect impact our business, results of operations and financial condition.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
Issues raised by the use of Artificial Intelligence (AI) and machine learning in our operations may subject us to new or heightened legal, regulatory, ethical or other concerns and result in liability or reputational harm. We have started to leverage AI in certain of our operations and implemented policies and controls to mitigate many of the novel risks presented by these new technologies. We face risks related to the incorporation of AI in our operations due to the challenges inherent with properly managing its use. There can be no assurance that our investments in AI will pay off. If our employees, customers or business partners do not comply, or are dissatisfied with, our policies and practices related to the use of such technologies we may experience legal, regulatory or reputational liability. Further, we need to continuously adapt to new laws and regulations such as the European Union's Artificial Intelligence (AI) Act, and others in the United States and other jurisdictions, regulating the use of these technologies, the impact and cost of which could be significant.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
Our operations, and the operations of our suppliers, distributors or customers, could be subject to natural and man made disasters as well as the impact of governmental actions and regulations in response to such events, any of which
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
We are subject to risks related to legal claims and proceedings filed by or against us, and adverse outcomes in these matters may materially harm our business. We are subject from time to time to various claims, disputes, investigations, demands, arbitration, litigation or other legal proceedings which may result in material damages, place restrictions on our business operations or divert our management's attention from other business issues and opportunities. Legal matters are
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
unpredictable and significant adverse judgments, penalties, settlement amounts or defense costs could materially and adversely affect our liquidity and capital resources. It is also possible that, as a result of a present or future governmental or other proceeding or settlement significant restrictions will be placed upon, or significant changes made to our business practices and operations. Any such restrictions or changes may adversely affect our profitability or increase our compliance costs. The unfavorable resolution of one or more of these matters could have a material and adverse impact on our business, results of operations and financial condition.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
The recent cuts in staff at the FDA's Center for Devices and Radiological Health may result in the FDA taking longer to review applications which could cause significant delays in regulatory approvals resulting in longer timelines to bring new medical devices to market for certain products in our Medical segment. We expect the effects of these uncertainties to impact our orders and sales in the near term, and adversely impact our business, results of operations and financial condition, although we are unable to predict the exact duration or magnitude of the impact.
Read it in 10-K Feb 26, 2025 at sec.gov
RewordedRisk Factors
The actual revenue, cost and gross profit realized on from these contracts can vary, sometimes substantially, differ substantially from original projections due to a variety of factors including inaccurate costs estimation, inflation, currency fluctuations, errors in specifications or designs, other unanticipated design error, technical problems with our products or services which require that we remedy the problem at our cost, problems, supplier failures, regulatory delays, customer difficulty in obtaining required governmental permits or approvals or other customer-caused delays, issues, changes in regulations and laws, construction delays of new NPPs and decommissioning of existing NPPs, delays, limited history with new products and customers, contract termination, or other unanticipated circumstances over the circumstances.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
If an author or other third party that distributes such open source software were to allege that we had not complied with the conditions of one or more of these licenses, we could be required to incur significant face costly legal expenses defending against such allegations disputes and could be subject to significant damages, enjoined from the sale of our products that contained the open source software and required to comply with the foregoing conditions, which could disrupt the distribution and sale of some of our products and adversely affect our business, results of operations and financial condition. software.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
If the nuclear liability and indemnification authority in the United States this protection is reduced or other countries is eliminated or adversely modified in the future, our business removed it could be materially and adversely affected if lead the owners and operators of NPPs cancel or delay plans to build new plants or curtail the operations of existing plants. plants, materially and adversely affecting our business.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
Any reduction in the resources or government funding of our customers, including funding, such as a result of a government shutdown, the U.S. government's failure to raise the debt ceiling, or other governmental action or order to reduce governmental budgets and spending generally, including in non-U.S. countries, general budget cuts could reduce our sales and impede our ability to generate revenue.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
International tariffs, including Our operating results may be impacted by the effects of, and changes in, worldwide economic conditions, international trade, tariffs that affect our products or components within our products, and retaliatory countermeasures, export controls and other trade barriers or barriers, global trade wars or domestic preferences which could increase our costs and materially and adversely affect our business, results of operations and financial condition.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
Our supply chains could also be disrupted by factors such as supplier Suppliers capacity constraints, operational or quality issues, bankruptcy bankruptcies or exiting of the other business for other reasons, terminations, decreased availability of key materials, and external events like natural disasters, pandemics, war, terrorism, tariffs wars and other governmental actions. actions can make it difficult to find replacements quickly or at similar costs.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
Many governments, Governments, regulators, investors, employees, customers, and other stakeholders are increasingly focused placing emphasis on the environmental, social and governance performance of companies, including their focus on climate change, greenhouse gas emissions, human and civil rights, diversity, equity and inclusion initiatives, companies with diverging varying and sometimes polar opposite goals and objectives. conflicting expectations.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
We operate in an industry where the risks associated with related to radioactive materials and the public perception of views on nuclear energy could materially and adversely affect the our markets in which we operate and increase regulatory requirements and costs that could in turn materially costs, negatively impacting our business, results of operations and adversely affect our business. financial condition.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
Our failure to comply with any Non-compliance or improper handling of these on-going obligations could radioactive materials can result in the revocation of the applicable license, license revocation, which could result in the cancellation or delay of purchases by our customers. customers, penalties, fines and liability for accidents or contamination.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
Additionally, certain of our some confidential information, information and customer data, may be data is gathered, processed, and stored on by third-party networks of vendors or service providers whom whose security and protection policies and procedures we have engaged. ultimately do not, and are unable to, control.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
Our business operations are subject to The Company operates under extensive regulation by various federal, state, and local governmental agencies in the United States and other countries in which we conduct business. business covering areas such as radioactive materials, antitrust, environmental, health and safety, food and drug, medical device, import/export, and labor laws.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
The Advertising and promotion of our products is closely monitored by the FDA requires that device and Federal Trade Commission to prevent false or misleading claims and manufacturers determine if must assess whether product modifications to approved products require new approvals, though the FDA can review these decisions.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesRisk Factors
These additional expenses will could place pressure on profit margins or require us to increase the price of our products and services potentially affecting demand and, consequently, our business, results of operations and financial condition.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
(2)Pre-tax non-operating expenses of $23.0 million for the year ended December 31, 2025, include $15.7 million of mergers and acquisitions costs associated with our acquisitions of Paragon and Certrec; $2.9 million of restructuring and other related costs; $1.9 million of consulting costs related to Nuclear & Safety segment enterprise resource planning implementations which were substantially completed as of December 31, 2025; $1.3 million of one-time consulting fees related to IT services sourcing excellence; and a $1.0 million asset impairment of an equity investment (100% impairment).
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
On May 23, 2025, the Company completed a private offering of $400.0 million aggregate principal amount of 0.25% Convertible Senior Notes due 2030 (the “2030 Notes”), which included the initial purchasers' exercise in full of their option to purchase additional 2030 Notes. The Notes have a maturity date of June 1, 2030. Refer to discussion included within Liquidity and Capital Resources for more details.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
On July 31, 2025, Mirion acquired 100% of the equity interest of Certrec for $82.9 million of purchase consideration ($80.6 million net of cash), subject to final closing statement balances. As part of the Nuclear & Safety segment, Certrec is a leading supplier of regulatory compliance and digital integration solutions for the energy industry. Mirion management believes the Certrec business will be pivotal in expanding our offerings in the nuclear power market and further strengthen the development of our digital ecosystem.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
On September 30, 2025, the Company completed a public offering of 19,906,322 shares of Mirion's Class A common stock at a public offering price of $21.35 per share, including the underwriters' exercise in full of their option to purchase additional shares. Additionally, on September 30, 2025, the Company completed a private offering of $375.0 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2031, including the initial purchasers’ exercise in full of their option to purchase additional Notes (the “2031 Notes” and, together with the 2030 Notes, the “Convertible Notes). The Notes have a maturity date of October 1, 2031. The Company used the net proceeds from the Class A common stock offering, together with the net proceeds from the offering of 2031 Notes, to fund the acquisition of all of the outstanding membership interests of WCI-Gigawatt Intermediate Holdco, LLC, as the indirect parent of Paragon Energy Solutions, LLC, for approximately $585.0 million pursuant to the equity purchase agreement signed September 24, 2025. Remaining funds from the offerings will be used for general corporate purposes and working capital. Refer to discussion included within Liquidity and Capital Resources for more details.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
On December 1, 2025, Mirion acquired 100% of the outstanding membership interest of WCI-Gigawatt Intermediate Holdco, LLC, the indirect parent of Paragon Energy Solutions, LLC (“Paragon”) for $588.4 million of gross purchase consideration ($581.3 million, net of cash and net working capital adjustment), subject to final closing statement balances. As part of the Nuclear & Safety segment, Paragon is a leading provider of highly engineered solutions for large-scale nuclear power plants and small modular reactors (SMRs) in the United States. Mirion management believes that Paragon will provide Mirion's nuclear power customers with a more comprehensive suite of product offerings and services to meet their growing needs. Additionally, the addition of Paragon significantly enhances our presence in the U.S. nuclear power market and the developing SMR commercial entrants.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
On June 5, 2025, the Company entered into Amendment No. 5 to the 2021 Credit Agreement ("Amendment No. 5"). Under Amendment No. 5, the Company utilized funds from the private offering of Convertible Senior Notes due 2030 completed on May 23, 2025 (see Note 9, Convertible Debt) to repay $244.6 million in outstanding principal and $8.3 million in accrued interest as well as to extend the maturity date of the term loan to June 5, 2032 (collectively, the "June 2025 Refinancing"). The June 2025 Refinancing was accounted for as a partial extinguishment and partial modification of the term loan debt. The Company accounted for $244.6 million of the term loan principal as an extinguishment of debt; the remaining $450.0 million of principal was accounted for as a modification to the extent the principal holdings at the syndicated lender level remained unchanged. As a result, the Company recorded a loss on partial debt extinguishment of $5.8 million within the Consolidated Statement of Operations for the period ended December 31, 2025 attributed to the derecognition of a proportionate amount of unamortized deferred financing costs.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
Revolving Line of Credit - The revolving line of credit arrangement initially had a five year term (expiring October 2026) and bore interest at the greater of LIBOR (through June 30, 2023) / SOFR (subsequent to June 2023) or 0%, plus 2.25%. The terms of the revolving line of credit were amended on March 21, 2025, through Amendment No. 4 to the 2021 Credit Agreement ("Amendment No. 4"). Under Amendment No. 4, revolving credit commitments from lenders increased from $90.0 million to $175.0 million, and the maturity date extended to March 21, 2030, subject to a "springing" maturity date that is 91 days prior to the maturity date of the outstanding term loan under the 2021 Credit Agreement (but only to the extent the outstanding principal amount of the term loan exceeds $100.0 million on the date of determination, and a final statement maturity date that is early than 91 days after March 21, 2030).
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
On May 23, 2025, the Company completed a private offering of $400.0 million in aggregate principal amount of 0.25% Convertible Senior Notes due 2030, including the initial purchasers’ exercise in full of their option to purchase additional Notes (the “2030 Notes”). The 2030 Notes were issued pursuant to an indenture, dated May 23, 2025 (the “May
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
Indenture”). The May Indenture includes customary covenants and sets forth certain events of default after which the 2030 Notes may be declared immediately due and payable and sets forth certain types of bankruptcy or insolvency events of default involving the Company after which the outstanding principal and accrued interest of the 2030 Notes becomes automatically due and payable.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
The 2030 Notes will mature on June 1, 2030, unless earlier converted, redeemed or repurchased. The 2030 Notes will bear interest from May 23, 2025 at a rate of 0.25% per year payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2025. The 2030 Notes will be convertible at the option of the holders in certain circumstances discussed below. The 2030 Notes will be convertible into cash, shares of Mirion’s Class A common stock or a combination of cash and shares of Mirion’s Class A common stock, at the Company’s election.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
The initial conversion rate is 43.2751 shares of Mirion’s Class A common stock per $1,000 principal amount of 2030 Notes, which is equivalent to an initial conversion price of approximately $23.11 per share of Mirion's Class A common stock. The initial conversion price of the 2030 Notes represents a conversion premium of 32.5% to the last reported sale price of Mirion’s Class A common stock of $17.44 per share on May 20, 2025. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the May Indenture.
Read it in 10-K Feb 19, 2026 at sec.gov
RemovedMD&A
(In millions) Year Ended December 31, 2024 Year Ended December 31, 2023 Year Ended December 31, 2022 Net loss $ (36.6) $ (98.7) $ (288.4) Interest expense, net 51.3 57.1 41.9 Income tax provision (benefit) 2.7 (6.6) (18.2) Amortization 118.5 131.3 145.8 EBITA $ 135.9 $ 83.1 $ (118.9) Depreciation 31.9 31.5 28.7 EBITDA $ 167.8 $ 114.6 $ (90.2) Stock-based compensation expense 15.6 21.9 31.8 Increase (decrease) in fair value of warrant liabilities 5.3 24.8 (37.6) Goodwill impairment — — 211.8 Other impairments(1) — — 7.0 Loss on debt extinguishment — 2.6 — Foreign currency loss (gain), net 2.2 (0.3) 4.9 Cost of revenues impact from inventory valuation purchase accounting — — 6.3 Non-operating expenses(2)(3)(4)(5) 12.7 17.1 30.7 Adjusted EBITDA $ 203.6 $ 180.7 $ 164.7
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
Year Ended December 31, 2022 (In millions) Medical Nuclear & Safety Corporate & Other Consolidated Income from operations $ (98.9) $ (103.1) $ (95.8) $ (297.8) Amortization 64.3 81.5 — 145.8 Depreciation 18.1 9.6 1.0 28.7 Cost of revenues impact from inventory valuation purchase accounting 0.9 5.4 — 6.3 Stock-based compensation 0.6 1.0 30.2 31.8 Goodwill impairment 87.3 124.5 — 211.8 Other impairments — 2.5 4.5 7.0 Non-operating expenses 14.6 2.6 13.8 31.0 Other income / expense — — 0.1 0.1 Adjusted EBITDA $ 86.9 $ 124.0 $ (46.2) $ 164.7
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
In April 2023, one of our Russian customers made a claim against the Company, including liquidated damages for certain delays under the terms of an active project, in the amount of $19.3 million, and sent an updated claim statement in October 2023 totaling $21 million ($18 million of which accrue daily penalties), subject to a $14 million contractual cap (all amounts converted from Euros to U.S. Dollars). In November 2024, the Company reached an agreement to modify the underlying contract and the claim was rescinded by the customer. The modification was accounted for under ASC 606 Revenue Recognition which resulted in an immaterial impact to the Consolidated Statement of Operations for the fiscal year ended December 31, 2024.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
In June 2023, the same Russian customer made a demand against the Company for the return of all payments received by the Company (totaling $10.2 million) related to a Finland nuclear power plant project cancelled in May 2022. In September 2024, the Company entered into a settlement agreement with the customer agreeing to refund €4.4 million to the customer. The amount is included in Accrued expenses and other current liabilities in the Consolidated Balance Sheet as of December 31, 2024, and the settlement resulted in an immaterial impact to the Consolidated Statement of Operations for the twelve months ended December 31, 2024.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
Global interest rates remained elevated during 2024 after the series of U.S. federal funds interest rate increases that have occurred since late 2022, with slight decreases since late 2023. The Company's 2021 Credit Agreement provides for an $830.0 million senior secured first lien term loan facility (maturing in October 2028) and a $90.0 million senior secured revolving facility (expiring and maturing in October 2026) (collectively, the “Credit Facilities”).
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
On April 3, 2023, the Company closed the sale of the Biodex Rehabilitation ("Rehab") business to Salona Global Medical Device Corporation ("Salona"). As a result, Rehab operating results are included in Mirion's operating results for the three months ended March 31, 2023.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
Subsequent to the closing and during the fiscal year ended December 31, 2023, significant events occurred that negatively impacted the Company's ability to collect the remaining $7.0 million of cash payments owed for the sale, including disclosure by Salona that substantial doubt existed as to its ability to continue as a going concern. The Company elected to apply ASC 450 Contingencies to determine the loss on the business disposal since remaining payments were contingent on Salona's financial situation. As a result a loss on sale of business of $6.5 million was recorded in the Consolidated Statement of Operations during the year ended December 31, 2023.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
During the fiscal year ended December 31, 2024, Salona paid $1.2 million of the amount owed for the sale, and accordingly the Company recorded the payment as a reversal of the contingent loss in the Consolidated Statements of
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
On November 1, 2023, the Company acquired ec2 Software Solutions LLC and NUMA LLC (collectively “ec2”) for $33 million of cash consideration. Headquartered in Somerset, NJ, ec2 is a medical software company that designs, implements, and supports comprehensive software solutions servicing the nuclear medicine industry. The ec2 team and portfolio of solutions were integrated as part of the Company's Medical segment. As a result, ec2 operating results are included in Mirion's operating results for the full twelve months ended December 31, 2024, but are only included for the final two months in fiscal year 2023.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
On April 18, 2024, the Company announced that it would redeem all Public Warrants that remained outstanding at 5:00 pm New York City time on Monday, May 20, 2024 (the "Redemption Date"). Holders had the option to exercise their warrants and receive the Company's Class A common stock (i) in exchange for a payment in cash of the $11.50 per warrant exercise price, or (ii) on a “cashless” basis in which the exercising holder received a number of shares of the Company's Class A common stock determined under the warrant agreement based on the redemption date and the redemption fair market value. The “fair market value” was based on the average last price per share of the Company's Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the Notice of Redemption was sent. Substantially all holders elected a cashless exercise in their redemption elections. In addition, on June 4, 2024, the Company entered into a warrant exchange agreement with GS Sponsor II LLC to issue an aggregate of 1,768,000 shares of the Company’s Class A common stock upon the exchange of 8,500,000 Private Placement Warrants.
Read it in 10-K Feb 26, 2025 at sec.gov
RewordedMD&A
The overall decrease increase in net loss income is primarily driven by increased revenues in both Medical and Nuclear & Safety and Medical segments, decreased amortization expense interest expense, a $17.4 million unrealized foreign currency gain as a result of fluctuations in the current year, lower selling, general and administrative costs associated with reduced
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Net cash used in investing activities was $694.6 million for the year ended December 31, 2025 as compared to net cash used of $43.7 million for the year ended December 31, 2024 as compared to net cash used of $64.7 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Nuclear & Safety Medical segment revenues increased $44.7 $11.1 million for the year ended December 31, 2024 2025 compared with the year ended December 31, 2023 2024 primarily due to price increases increases, recovery from operational delays in the comparable prior period, foreign exchange fluctuations, and organic volume growth, partially offset by projects execution timing. growth.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
On a segment basis, income from operations in the Medical Nuclear & Safety segment was $101.1 million and $78.9 million for the year ended December 31, 2023 was $13.0 million 2025 and loss from operations for the year ended December 31, 2022 was $98.9 million, 2024, respectively, representing an increase of $111.9 $22.2 million.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Income from operations was $46.9 million for the year ended December 31, 2025 and loss from operations was $22.3 million for the year ended December 31, 2024 and loss from operations was $13.0 million for the year ended December 31, 2023, 2024, respectively, representing an increase in income from operations of $9.3 $24.6 million.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
The increase in income from operations period over period was largely due to the increased revenues noted previously, improved margin mix, a reduction in amortization expense of $7.3 million, lower bonus expenses restructuring and related impairment costs of $3.3 $3.4 million, and a net impact from the ec2 business lower compensation costs of $1.9 $1.6 million.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
As such, we entered into an interest rate swap (notional amount of $75.0 million) during the year ended December 31, 2024, 2023, as well as an additional interest rate swap (notional amount of $100.0 million) during the year ended December 31, 2025 to mitigate the risk of adverse changes in benchmark interest rates on the Company's future interest payments. payments (collectively, the "interest rate swaps").
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Research and development (“R&D”) expenses were $38.9 million for the year ended December 31, 2025 and $35.0 million for the year ended December 31, 2024 and $31.7 million for the year ended December 31, 2023, 2024, resulting in a an increase of $3.3 $3.9 million.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
We recorded a gain of $17.4 million for the year ended December 31, 2025 and a loss of $2.2 million for the year ended December 31, 2024 and a gain of $0.3 million for the year ended December 31, 2023 from foreign currency exchange.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Income from operations was $101.1 million for the year ended December 31, 2025 and $78.9 million for the year ended December 31, 2024 and loss from operations was $46.0 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Partially offsetting the increase in Medical segment revenues period over period were reduced revenues from China and Russia orders compared to the prior year and reduced revenues from the disposal of the Rehab business in the prior year (see Note 2, Business Combinations, Acquisitions, and Business Disposals, to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K).
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
For more discussion of on the hedges of net investments, Company's debt profile, see Note 17, Fair Value Measurement, 8, Borrowings, and Note 18, Derivatives and Hedging, 9, Convertible Debt, to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesMD&A
The Amendment No. 3 reduced the applicable margin rate on the term loans from 2.75% to 2.25% and reduced the credit spread based upon rate term to 0%, with other terms and conditions remaining consistent (effectively the existing loan was refinanced).
Read it in 10-K Feb 19, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MIR/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.